<DOC>
	<DOCNO>NCT02104336</DOCNO>
	<brief_summary>Treatment Pediatric Subjects Pearson syndrome</brief_summary>
	<brief_title>Phase 2 Study EPI-743 Children With Pearson Syndrome</brief_title>
	<detailed_description>If effective , treatment EPI-743 result significant reduction occurrence sepsis , metabolic crisis , hepatic failure transfusion dependence .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lipid Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Genetically confirm diagnosis Pearson syndrome Age le 18 Availability medical history 12 month prior enrollment Abstention use CoQ10 , vitamin E , lipoic acid Idebenone 14 day prior treatment EPI743 Allergy EPI743 , sesame oil vitamin E Clinical history bleeding/ abnormal PT/PTT Concurrent inborn error metabolism Use anticoagulant medication Participation interventional study within 30 day treatment Use erythropoietin 30 day prior trial enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Pearson</keyword>
	<keyword>EPI743</keyword>
	<keyword>EPI-743</keyword>
	<keyword>Vincerinone</keyword>
	<keyword>Mitochondrial disorder</keyword>
	<keyword>Mitochondrial disease</keyword>
</DOC>